Related Experiment Video

Updated: Jun 11, 2026

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease
06:25

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease

Published on: March 29, 2024

Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth

T Botton1, A Puissant, Y Cheli

  • 1INSERM, U895, équipe 1 Nice, France.

Cell Death and Differentiation
|July 3, 2010
PubMed

Insights

The thiazolidinedione ciglitazone inhibits melanoma growth by downregulating the MITF/CXCL1 pathway. This targeted approach reduces tumor development and offers a new therapeutic strategy for melanoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Dermatology

Background:

  • The thiazolidinedione ciglitazone demonstrates anti-melanoma properties independent of PPARγ activation.
  • Previous research indicated ciglitazone's inhibitory effect on melanoma cell growth.

Purpose of the Study:

  • To elucidate the mechanisms underlying ciglitazone's anti-melanoma effects.
  • To investigate the role of secreted factors and gene expression in ciglitazone's action.

Main Methods:

  • Quantitative PCR (Q-PCR) screening of melanoma-associated genes.
  • Analysis of CXCL1 chemokine expression and its regulation by microphthalmia-associated transcription factor (MITF).
  • In vivo studies using nude mice to assess tumor development inhibition.

Main Results:

  • Ciglitazone downregulates the expression of the CXCL1 chemokine gene in human melanoma cell lines.
  • This downregulation is mediated by reduced levels of MITF, a key transcription factor in melanoma.
  • Recombinant CXCL1 protein counteracted ciglitazone's pro-apoptotic effects, while CXCL1 pathway inhibition mimicked ciglitazone's effects.
  • Ciglitazone treatment significantly reduced tumor growth in mice, correlating with decreased MITF and CXCL1 levels.

Conclusions:

  • The anti-melanoma effects of ciglitazone are mediated through the inhibition of the MITF/CXCL1 axis.
  • The MITF/CXCL1 pathway plays a crucial role in melanoma progression and malignancy.
  • Targeting this axis represents a potential therapeutic strategy for melanoma treatment.

More Related Videos

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...